Peptide Initiative

Peptides · Peptide comparison

BPC-157 vs Intermedin (Adrenomedullin-2)

The "Wolverine peptide" known for its remarkable healing properties across tendons, ligaments, muscles, and the gut.

A powerful peptide hormone that protects your heart and blood vessels while managing stress and inflammation naturally.

  • Healing & Recovery
  • Healing & Recovery

At a glance

Quick comparison

Dose rangeBPC-157250–500 mcgIntermedin (Adrenomedullin-2)As prescribed–As prescribed mg
FrequencyBPC-157Once dailyIntermedin (Adrenomedullin-2)Once daily
AdministrationBPC-157Subcutaneous injectionIntermedin (Adrenomedullin-2)As directed by healthcare provider
Cycle lengthBPC-1574-6 weeksIntermedin (Adrenomedullin-2)Ongoing/indefinite
Onset speedBPC-157Moderate (1-2 weeks)Intermedin (Adrenomedullin-2)Moderate (1-2 weeks)
Evidence levelBPC-157Strong preclinical (extensive animal studies)Intermedin (Adrenomedullin-2)Limited human trials

Efficacy

Benefit ratings

Primary Benefit

BPC-15785%
Intermedin (Adrenomedullin-2)No recorded rating

Secondary Benefit

BPC-15778%
Intermedin (Adrenomedullin-2)No recorded rating

Additional Benefit

BPC-15772%
Intermedin (Adrenomedullin-2)No recorded rating

Cardiovascular Health & Protection

BPC-157No recorded rating
Intermedin (Adrenomedullin-2)72%

Stress & Anxiety Management

BPC-157No recorded rating
Intermedin (Adrenomedullin-2)68%

Anti-Inflammatory & Antioxidant Support

BPC-157No recorded rating
Intermedin (Adrenomedullin-2)64%

Technical data

Compound specifications

BPC-157

Molecular formula
C62H98N16O22
Molecular weight
1419.53 g/mol
Half-life
4-6 hours
Bioavailability
~100% (subcutaneous)
CAS number
137525-51-0

Intermedin (Adrenomedullin-2)

Molecular formula
C15H25NO5 (precursor compound)
Molecular weight
299.36 g/mol (precursor)
Half-life
Approximately 2-6 hours (varies by route of administration)
Bioavailability
Varies by route of administration
CAS number
148498-78-6

Protocols

Dosing compared

BPC-157

Subcutaneous

  • 250 mcgOnce daily · 1-2 weeksA common starting amount in research practice, often injected near the injured area. BPC-157 has no human dose-finding trials, so doses come from animal studies and documented practice [1][2].
  • 250-500 mcgTwice daily · 4-6 weeksCommonly used range for tissue and tendon recovery in research practice [1][3].
  • 500 mcgTwice daily · 6-8 weeksUpper end used in practice for more demanding acute injuries [1][3].

Intermedin (Adrenomedullin-2)

No dose levels recorded.

Applications

Best suited for

BPC-157

Tendon and ligament injuries
Sprains, strains, tears, tendinitis - BPC-157 accelerates collagen synthesis and tissue repair [1][7]
Gut healing
IBS, leaky gut, ulcers, inflammatory bowel conditions [1][11] - derived from gastric juice, it has a natural affinity for digestive tissue [3][5]
Muscle injuries
Strains, post-workout recovery, chronic muscle issues - promotes angiogenesis and growth factor expression [8]
Joint problems
Arthritis support, joint pain, cartilage issues - anti-inflammatory and regenerative properties [9][10]
Post-surgical recovery
Accelerating healing after procedures - works systemically to enhance the body's repair mechanisms [2]

Intermedin (Adrenomedullin-2)

Supporting cardiovascular health and heart function
Intermedin (Adrenomedullin-2) is particularly well-suited for individuals focused on supporting cardiovascular health and heart function. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Managing inflammation and oxidative stress
Intermedin (Adrenomedullin-2) is particularly well-suited for individuals focused on managing inflammation and oxidative stress. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Improving overall vascular health and circulation
Intermedin (Adrenomedullin-2) is particularly well-suited for individuals focused on improving overall vascular health and circulation. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Safety profile

Side effects

BPC-157

Common

  • Injection site redness
  • Mild nausea
  • Dizziness

Uncommon

  • Headache
  • Fatigue
  • Hot/cold sensations

Serious

  • Allergic reaction

Intermedin (Adrenomedullin-2)

Common

  • Mild discomfort at treatment site
  • Flushing and mild facial redness
  • Dizziness or lightheadedness
  • Mild headache
  • Injection site reactions (redness, itching, swelling)
  • Nausea or mild gastrointestinal discomfort
  • Fatigue or mild energy changes
  • Transient hypotension (temporary low blood pressure)
  • Mild palpitations (in some individuals)

Serious

  • Severe allergic reaction

Research status

Safety & evidence

BPC-157

Evidence level
Strong preclinical (extensive animal studies)
FDA status
Research compound
Safety overview
BPC-157 is a gastric pentadecapeptide with strong preclinical evidence from extensive animal studies spanning over 25 years of research. Critical limitation: BPC-157 has NOT completed Phase 3 human clinical trials. [5] No FDA approval exists. [4][6] Safety data comes primarily from rat and mouse studies, with only limited Phase 1-2 human data. [4][5] Animal studies show no toxicity at therapeutic doses, but human data is insufficient for regulatory approval. [2][4] The peptide is unregulated, and no standardized manufacturing or quality control requirements exist for research compounds. [6][7] Individual responses may vary significantly, and serious medical supervision is essential before use, particularly if you have gastrointestinal conditions, take medications, or have pre-existing medical conditions.

Contraindications

  • Pregnancy
  • Breastfeeding
  • Active cancer
  • History of cancer

Intermedin (Adrenomedullin-2)

Evidence level
Limited human trials
FDA status
Not FDA approved
Safety overview
Intermedin (Adrenomedullin-2) is an endogenous peptide hormone with systemic vascular and renal effects that warrant cautious use. As a vasodilator acting through CGRP and other peptide receptors, it can significantly lower blood pressure—a key safety consideration for hypotensive or cardiovascular-compromised individuals. Preclinical studies show dose-dependent hypotensive effects and tachycardia, limiting clinical translation. The compound remains largely experimental with limited safety data in humans outside specific research contexts.

Contraindications

  • Pregnancy and breastfeeding - insufficient safety data
  • Active cardiovascular events (heart attack, stroke)
  • Severe renal (kidney) impairment
  • Hypersensitivity to calcitonin family peptides
  • Uncontrolled endocrine disorders

Decision guide

Which is right for you?

BPC-157

Choose BPC-157 if…

  • Injury recovery
  • Post-surgery healing
  • Chronic pain management
  • Gut health

Intermedin (Adrenomedullin-2)

Choose Intermedin (Adrenomedullin-2) if…

  • Supporting cardiovascular health and heart function
  • Managing inflammation and oxidative stress
  • Improving overall vascular health and circulation